

NOVO NORDISK EXPAND APAS® USE WITH ORDER FOR TWO APAS® INDEPENDENCE INSTRUMENTS

The order includes development of custom laboratory interface software to enable potential global technology deployment

Adelaide, Australia, 07 September 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (CCS or the Company), is pleased to announce a purchase order from Novo Nordisk for two additional APAS® Independence instruments.

Highlights:

- Novo Nordisk orders two additional APAS® Independence instruments increasing its installed base to three
- Purchase order includes development of an advanced integration solution for Novo Nordisk's global Laboratory Information Management Solution (LIMS)
 - This is an important enabling step to support future expansion of the APAS® technology across additional Novo Nordisk global manufacturing sites
- Follows successful evaluation of APAS® technology over the past 12 months, with positive results presented at APAS® Expert User Group meeting
- Company restates expectations of a step-change increase in sales commencing FY27, largely driven by sales expansion with existing customers plus new customer opportunities converting to sales

Brent Barnes, CCS CEO and Managing Director said:

"This order from Novo Nordisk is a further demonstration of the APAS® technology performance and provides evidence of our long-stated Land and Expand strategy targeting major global pharmaceutical manufacturers. Sterile drug manufacturing companies rightly undergo a rigorous process when introducing new technologies into their manufacturing network. Patient safety, data integrity and regulatory compliance is critical, and we have designed APAS® from the outset to meet these requirements and to integrate into our customers' systems.

Importantly, we are now seeing the early benefits of the customer base we have established over the past two years. As these customers progress from evaluation and initial adoption towards broader deployment, we expect expansion from existing customers to become the major driver of a step-change in sales from FY27 and beyond."

Novo Nordisk place order for two APAS® Independence instruments to commence formal validation of APAS®

CCS has received a purchase order from Novo Nordisk for two additional APAS® Independence instruments, following successful evaluation of the technology. The order increases the total number of instruments purchased by Novo Nordisk to three. The sales price for each of the two instruments is consistent with previously disclosed targeted pricing.

The instruments will be installed at a single site in Denmark and used to complete a formal global validation of the APAS® technology. Successful completion will allow the instruments to transition into routine laboratory use supporting the regulatory required Good Manufacturing Practice (GMP). This represents the final technology performance milestone required by Novo Nordisk ahead of potential broader deployment.

In addition to the instrument order, Novo Nordisk also placed an order with CCS to commence work on an advanced interface between their global Laboratory Information Management System (LIMS) and APAS® technology. The interface will support a bi-directional communication between LIMS and the APAS® instrument to allow for more intelligent sorting of environmental monitoring samples, ultimately driving greater value from the instrument.


Novo Nordisk order is an early demonstration of FY27 positive Land and Expand sales outlook

Novo Nordisk purchased their first APAS® Independence instrument in July 2025 ([Announcement](#)). This first instrument was purchased to support an initial global evaluation of the technology to determine potential suitability for use across the Novo

Nordisk manufacturing network. Following successful completion of the evaluation, the two additional instruments ordered will support a formal validation of the technology.

The progression with Novo Nordisk demonstrates CCS's Land and Expand sales strategy targeting large multi-site global pharmaceutical manufacturers. CCS has now installed APAS® Independence with 8 global manufacturers, each progressing through different stages of evaluation, validation and deployment. While each customer follows their own processes and timelines, CCS is focused on progressing them towards routine GMP use and broader roll out.

With the global pharmaceutical customer base established over the past two years, CCS expects expansion within existing customers to become an increasingly important driver of instrument sales from FY27 and beyond. The graphic below summarises the current status and expansion opportunity across this multi-site pharmaceutical cohort; it does not represent CCS's total customer base:



Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com